PSA-tests bij mannen ouder dan 74 jaar: zwart-wit of toch een grijs gebied?

Translated title of the contribution: PSA based screening in men over the age of 74 years: a black-and-white issue or a grey area?

Sebastiaan Remmers, Renée Hogenhout, ERSPC Rotterdam Study Group, Monique J. Roobol*

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

3 Downloads (Pure)

Abstract

Men >70–74 years of age are excluded from PSA-based screening for prostate cancer because of overdiagnosis. In this study we will determine if we should apply PSA-based screening in elderly in terms of life expectancy and quality of life. Men aged between 70–74 years randomly assigned in the screening group of the Dutch ERSPC and not diagnosed with prostate cancer at time of screening were included. Incidence and mortality were described. In the end 3,040 men were included. During a follow up of 24 years, 202 (7%) were diagnosed with prostate cancer of which 52 (26%) developed metastasis and 26% died of prostate cancer. PSA at time of screening predicted prostate cancer specific mortality (PCSM). Concluded was that men > 74 years of age should not be refrained from screening given the risk of metastasis and the mortality rate. Health assessment and counseling together with PSA testing and further risk stratification are the key to a valid screening strategy.

Translated title of the contributionPSA based screening in men over the age of 74 years: a black-and-white issue or a grey area?
Original languageDutch
Pages (from-to)22-32
Number of pages11
JournalTijdschrift voor Urologie
Volume11
Issue number2-3
DOIs
Publication statusPublished - Mar 2021

Bibliographical note

Publisher Copyright:
© 2021, The Author(s).

Fingerprint

Dive into the research topics of 'PSA based screening in men over the age of 74 years: a black-and-white issue or a grey area?'. Together they form a unique fingerprint.

Cite this